Abbott Labs Prevails at Trial in Ohio Federal Depakote Birth Defect Action

CLEVELAND — An Ohio federal jury has rendered a verdict in favor of Abbott Laboratories Inc. in a Depakote birth defect action, finding the drug maker did not fail to adequately warn the plaintiffs of the risks posed by the anti-seizure drug.

On Feb. 2, the jury, sitting in the U.S. District Court for the Northern District of Ohio, further determined that Depakote was not defective and that plaintiffs are not entitled to damages for loss of consortium. Judge Christopher Boyko of the U.S. District Court for the Northern District of Ohio presided over the 12-day trial.

At the conclusion …